Left ventricular remodelling following experimental myocardial infarction.
Experimental myocardial infarction is a model of cardiac overload in which part of the cardiac muscle is removed. The resulting left ventricle insufficiency depends on the size of the infarct and time. The infarcted area remodels, due to proteolytic activity of inflammatory cells and collagenogenesis from fibroblast activity. The phenotype of the residual healthy cardiac muscle undergoes modification, and there are peripheral vascular changes which are partly dependent on the activation of pressor systems and/or inactivation of dilator systems. The changes are proportional to the infarct size at any given time after induction of the model. The degree of right ventricular hypertrophy and the drop in arterial pressure are upstream and downstream markers of the loss of left ventricular function and therefore indicate the extent of the remodelling. The increase of type V3isomyosin, the amount of subendocardial collagen, and the biosynthesis, storage and secretion of atrial natriuretic factor (ANF) are all proportional to the infarct size and the degree of cardiac overload. The level of urinary cGMP is also correlated with infarct size. These indices show ventricular remodelling, increased stress and energy restriction of the residual healthy cardiac muscle. The activation of peripheral pressor systems also depends on infarct size. They reflect the influence of defective cardiac pumping on the kidney, liver, brain and endothelium. Massive infarcts are accompanied by an increase in circulating renin and in renal renin content, by a decrease in angiotensinogen due to its consumption by renin, and to its insufficient hepatic synthesis, and by an increase in vasopressin secretion and biosynthesis in the hypothalamus. Converting enzyme inhibition has beneficial effect in this model by lowering cardiac load. It reduces arterial pressure, reverses bi-atrial and right ventricular hypertrophy, reduces the changes in the myosin isoenzyme patterns, and normalizes subendocardial fibrosis and the level of ANF. Although the effects of converting enzyme inhibition are beneficial in this model, they are restricted by their inability to normalize the load and stress when the initial loss of cardiac contractile material exceeds 40%.
Michel
J B
JB
INSERM Unit 367, Didot, France.
Nicolletti
A
A
Arnal
J F
JF
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000808:Angiotensinogen / Q000378:metabolism; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D006152:Cyclic GMP / Q000652:urine; D017379:Hypertrophy, Left Ventricular / Q000209:etiology* / Q000378:metabolism; D007211:Indoles / Q000494:pharmacology; D007527:Isoenzymes / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D009203:Myocardial Infarction / Q000150:complications* / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D009218:Myosins / Q000378:metabolism; D020913:Perindopril; D051381:Rats; D017208:Rats, Wistar; D012083:Renin / Q000378:metabolism; D014667:Vasopressins / Q000378:metabolism; D018487:Ventricular Dysfunction, Left / Q000209:etiology* / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; D007527:Isoenzymes; D014667:Vasopressins; D000808:Angiotensinogen; D009320:Atrial Natriuretic Factor; D003094:Collagen; D012083:Renin; D009218:Myosins; D006152:Cyclic GMP; D020913:Perindopril